Carlo A Pivato, Bernhard Reimers, Luca Testa, Andrea Pacchioni, Carlo Briguori, Carmine Musto, Giovanni Esposito, Raffaele Piccolo, Luigi Lucisano, Leonardo De Luca, Federico Conrotto, Andrea De Marco, Anna Franzone, Patrizia Presbitero, Giuseppe Ferrante, Gerolama Condorelli, Valeria Paradies, Gennaro Sardella, Ciro Indolfi, Gianluigi Condorelli, Giulio G Stefanini
Background It is unknown whether contemporary drug-eluting stents have a similar safety profile in high bleeding risk patients treated with 1-month dual antiplatelet therapy following percutaneous coronary interventions. Methods and Results We performed an interventional, prospective, multicenter, single-arm trial, powered for noninferiority with respect to an objective performance criterion to evaluate the safety of percutaneous coronary interventions with Synergy bioresorbable-polymer everolimus-eluting stent followed by 1-month dual antiplatelet therapy in patients with high bleeding risk...
February 3, 2022: Journal of the American Heart Association